BMS-817378 Catalog No.:M23243-C Smiles: COC1C=C(C=C(OC)C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1OC[C@](O)(CO)[C@H]1O)[C@@H]1OC[C@@H]2[C@H]1CO[C@H]2C1=CC(OC)=C(O)C(=C1)OC

Smiles: COC1C=C(C=C(OC)C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1OC[C@](O)(CO)[C@H]1O)[C@@H]1OC[C@@H]2[C@H]1CO[C@H]2C1=CC(OC)=C(O)C(=C1)OC

20263-07-4

Zellefrow CD

CAS Number: 137592-45-1

Overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO

BMS-817378 Catalog No.:M23243-C Smiles: COC1C=C(C=C(OC)C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1OC[C@](O)(CO)[C@H]1O)[C@@H]1OC[C@@H]2[C@H]1CO[C@H]2C1=CC(OC)=C(O)C(=C1)OCDescription: IC50: 1. 7 nM 15 nM for Met VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression. BMS 817378 is a potent ATP competitive inhibitor of Met VEGFR2. In vitro: BMS 794833, which is the active